Scleroderma Esophagus: Optimizing PPI and Prokinetic Therapy for Severe Hypomotility
Severe esophageal hypomotility from systemic sclerosis has already outpaced what a standard PPI dose can protect against, raising a genuine question about how aggressively to layer acid suppression and prokinetic therapy on a gut whose underlying motor problem no drug in either class actually reverses.
Colette F., 56, was diagnosed with limited cutaneous systemic sclerosis nine years ago, and has adapted her life around it in ways her rheumatologist only learns about incidentally — she mentioned today, almost in passing, that she stopped hosting her book club's potluck nights two years ago because eating in front of people had become something she'd rather avoid. Manometry six months ago showed absent peristalsis throughout the esophageal body with a hypotensive LES, the classic pattern of scleroderma esophagus, and her reflux symptoms have progressed despite standard-dose omeprazole to the point that she now sleeps propped on three pillows and still wakes with a sour taste most mornings. Repeat endoscopy last month showed LA Grade B esophagitis despite that ongoing PPI therapy — real, objective evidence that standard dosing is no longer adequately controlling her acid exposure, not just a symptom-reporting gap.
The underlying motor problem itself doesn't respond to either drug class being discussed — absent peristalsis in scleroderma reflects smooth-muscle fibrosis, not a receptor deficiency a prokinetic could correct the way it might in a functional motility disorder. What acid suppression and prokinetic therapy can each do is reduce the volume and duration of reflux exposure her nonfunctioning esophageal body can no longer clear on its own once it happens. High-dose PPI therapy addresses the acid itself; a prokinetic like metoclopramide or prucalopride, working through different receptor mechanisms, can modestly increase LES tone and accelerate gastric emptying, indirectly reducing how much material is available to reflux in the first place — two genuinely complementary approaches to the same downstream problem, each with its own real limitations and side-effect profile.
"Absent peristalsis" means something specific on her tracing: none of her esophageal body contractions generate meaningful propulsive pressure at all, meaning gravity and positioning do essentially all the clearing work her smooth muscle no longer performs — a mechanical reality neither acid suppression nor a prokinetic reverses, which is exactly why the rheumatologist's insistence on treating her positioning and aspiration risk as their own explicit problem, not a downstream benefit of the drug regimen, is the right frame rather than an afterthought.
Layering therapy on a motor problem neither drug reverses
Her repeat endoscopy is the piece I keep coming back to: Grade B esophagitis despite standard-dose omeprazole is objective evidence, not a symptom-reporting gap, that current dosing isn't adequate anymore. I'd increase to a high, twice-daily PPI dose first, since that's the most direct fix for the most clearly documented gap in her current regimen.
I'd add a prokinetic alongside the PPI increase rather than rely on acid-dose escalation alone. Her actual problem is that material sits in a nonfunctioning esophagus with nothing to clear it — increasing acid suppression reduces how corrosive what's there is, but doesn't address the fact that it's there in the first place. A prokinetic that improves LES tone and gastric emptying attacks a different part of the same mechanism.
If we're adding a prokinetic for what's likely years of ongoing use in a progressive disease, I'd specifically favor prucalopride over metoclopramide — metoclopramide's tardive dyskinesia risk is real and cumulative with extended use, which matters a great deal more for lifelong therapy than for a short course.
I support both of those changes, but I want the nocturnal cough she mentioned addressed directly rather than folded silently into 'better reflux control should help that too.' Given how impaired her esophageal clearance already is, I'd want a real evaluation for silent aspiration — not assumed to resolve as a side effect of whichever regimen wins this conversation.
I'll add explicit positioning counseling (head-of-bed elevation, no reclining within three hours of eating) today regardless of which prokinetic we land on, since that part of the plan isn't actually in dispute.
Agreed: PPI increased to twice-daily dosing, prucalopride added rather than metoclopramide given the long-term-use consideration, explicit positioning/meal-timing counseling given today, and a pulmonary referral placed to evaluate her nocturnal cough for possible silent aspiration rather than assuming it will resolve alongside better reflux control.